Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.
Christian F. Singer(Medical University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Florian Fitzal, Angelika Pichler, Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Lidija Soelkner(Austrian Breast & Colorectal Cancer Study Group), Georg Pfeiler(Medical University of Vienna), Michael Seifert(Zimmer Biomet (Germany)), Edgar Petru(Medical University of Graz), Christoph Suppan(Medical University of Graz), Rupert Bartsch(Universitätszahnklinik Wien), Richard Greil(Paracelsus Medical University)
Cited by 6
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830